Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Oncophage enters phase II sarcoma study; trial marks drug's seventh cancer indication

Oct. 23, 2000

Status of Dendreon's dendritic cell-based vaccines updated

Oct. 19, 2000

Maxamine inhibits sarcomas in preclinical study

Oct. 19, 2000

Roche begins E.U. launch for Herceptin

Oct. 11, 2000

Two dendritic/cancer cell fusion trials begun by Genzyme Molecular Oncology

Oct. 9, 2000

InterMune to commence Actimmune clinical trial in ovarian cancer

Oct. 4, 2000

FDA completes review of supplemental BLA for Rituxan

Oct. 2, 2000

O-Vax ovarian cancer vaccine awarded orphan drug status in U.S.

Sep. 29, 2000

Corixa to file Melacine BLA for stage II melanoma

Sep. 29, 2000

Immunomedics commences phase III clinical trial with LymphoCide

Sep. 28, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....